Globenewswire·2026-03-05 13:30Core Insights - Tenaya Therapeutics has entered a research collaboration agreement with Alnylam Pharmaceuticals to discover novel genetic targets for cardiovascular disease treatments, with potential payments totaling up to $1.14 billion [1][2] Group 1: Agreement Details - Tenaya will receive up to $10 million in upfront payments, along with research funding and milestone payments that could reach $1.13 billion if all identified gene targets lead to approved therapeutics [1][2] - The collaboration involves validating up to 15 gene targets, with Alnylam responsible for all development and commercialization activities related to these targets [2] Group 2: Tenaya's Capabilities - Tenaya has developed a diverse portfolio of proprietary capabilities for target identification and validation, utilizing human induced pluripotent stem cell-derived cardiomyocytes and advanced technologies like machine learning [3] - The company has generated over 150 genetic targets and is advancing clinical-stage candidates such as TN-201 and TN-401, which are gene therapies for specific heart conditions [3][4] Group 3: Company Overview - Tenaya Therapeutics is focused on discovering and delivering potentially curative therapies for heart disease, with a pipeline that includes gene therapies and small molecules aimed at treating both rare and prevalent heart conditions [4]